| Company Name: |
Nextpeptide Inc |
| Tel: |
+86-0571-81612335 +8613336028439 |
| Email: |
sales@nextpeptide.com |
| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
Cindunistat ,PF-00572986
PHA-84250 manufacturers
- Cindunistat
-
- $258.00
-
2026-07-27
- CAS:364067-22-1
- Purity: 99.92%
- Supply Ability: 10g
|
| | Cindunistat ,PF-00572986
PHA-84250 Basic information |
| Product Name: | Cindunistat ,PF-00572986
PHA-84250 | | Synonyms: | Cindunistat ,PF-00572986
PHA-84250;S-[2-[(1-iminoethyl) amino]ethyl]-2-methyl-L-custeine;(R)-3-((2-Acetimidamidoethyl)thio)-2-amino-2-methylpropanoic acid;L-Cysteine, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-;Cindunistat | | CAS: | 364067-22-1 | | MF: | C8H17N3O2S | | MW: | 219.3 | | EINECS: | | | Product Categories: | | | Mol File: | 364067-22-1.mol |  |
| | Cindunistat ,PF-00572986
PHA-84250 Chemical Properties |
| Boiling point | 371.9±52.0 °C(Predicted) | | density | 1.27±0.1 g/cm3(Predicted) | | pka | 2.11±0.10(Predicted) |
| | Cindunistat ,PF-00572986
PHA-84250 Usage And Synthesis |
| Uses | Cindunistat (SD-6010) is a potent, orally active and selective iNOS inhibitor[1]. | | References | [1] Hellio le Graverand MP, et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013;72(2):187-195. DOI:10.1136/annrheumdis-2012-202239 |
| | Cindunistat ,PF-00572986
PHA-84250 Preparation Products And Raw materials |
|